MarketCap
Facebook
X
TelegramAnnual report 2023
added 12-27-2025
Centogene N.V. Operating Income 2011-2026 | CNTG
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -46 M | -19.7 M | -18.7 M | -10.6 M | -4.46 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.46 M | -46 M | -19.9 M |
Quarterly Operating Income Centogene N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -10.5 M | - | -21.3 M | -7.68 M | -13.9 M | - | -4.74 M | -10.1 M | -8.16 M | - | -2.84 M | -6.08 M | -4.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.84 M | -21.3 M | -9.02 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biomerica
BMRA
|
-5.14 M | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
912 M | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-33.3 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
-36.7 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-437 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
-541 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
62 M | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |